ICU Medical (NASDAQ:ICUI) Lowered to Hold Rating by StockNews.com

ICU Medical (NASDAQ:ICUI) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Thursday.

A number of other equities research analysts also recently commented on the company. Raymond James set a $97.00 target price on ICU Medical in a research report on Wednesday, March 12th. Jefferies Financial Group raised ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price objective on the stock in a report on Wednesday, December 11th. Two research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $168.67.

ICU Medical Price Performance

ICUI stock traded down $4.43 during mid-day trading on Thursday, hitting $144.28. The company had a trading volume of 171,682 shares, compared to its average volume of 256,501. The company has a 50-day moving average price of $154.89 and a 200 day moving average price of $164.01. ICU Medical has a 12-month low of $93.36 and a 12-month high of $196.26. The company has a market capitalization of $3.54 billion, a price-to-earnings ratio of -31.57 and a beta of 0.73. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75.

Insider Activity at ICU Medical

In other ICU Medical news, CEO Vivek Jain sold 1,373 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $155.48, for a total transaction of $213,474.04. Following the sale, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at $16,262,119.64. The trade was a 1.30 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 6.70% of the stock is owned by insiders.

Institutional Investors Weigh In On ICU Medical

Several institutional investors have recently modified their holdings of the stock. Vise Technologies Inc. raised its holdings in ICU Medical by 7.1% during the 4th quarter. Vise Technologies Inc. now owns 2,649 shares of the medical instruments supplier’s stock valued at $411,000 after buying an additional 176 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in ICU Medical by 20.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 51,531 shares of the medical instruments supplier’s stock worth $7,996,000 after buying an additional 8,789 shares during the period. Woodline Partners LP increased its position in ICU Medical by 4.5% during the fourth quarter. Woodline Partners LP now owns 122,239 shares of the medical instruments supplier’s stock valued at $18,968,000 after acquiring an additional 5,300 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in shares of ICU Medical in the fourth quarter valued at $3,236,000. Finally, Tidal Investments LLC bought a new stake in shares of ICU Medical in the 4th quarter worth about $342,000. 96.10% of the stock is owned by institutional investors.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.